TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics was prepared and expected ENHANCE Part B trial challenges, and will execute Part B hoping for significant success
80% confidenceOperating margins are expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting the timing and scale of investments
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceCompany is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceTotal revenue for Q4 was approximately $161 million with U.S. transplant revenue at approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceLiver share gains are pure TransMedics execution excellence
80% confidenceTransMedics delivered 'our best operational performance to date' and achieved results despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceThe makers of the styrofoam box technology are refusing to randomize their technology against TransMedics in ENHANCE Part B trial
80% confidenceTransMedics achieved its best operational performance to date in Q4 2025 despite external challenges designed to distract and disrupt growth
80% confidenceMost lung centers were waiting to see FDA approval before launching into DENOVO program
80% confidenceTransMedics is laser-focused on ensuring successful execution of these initiatives throughout 2026
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceTransMedics has huge opportunities ahead but also a few challenges and moving dynamics, which were factored into realistic guidance
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics is laser-focused on ensuring successful execution of 2026 initiatives
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceThe makers of that styrofoam box is refusing to randomize their technology to ours in ENHANCE Part B
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidence